[1] J.D. Bui, B. Kimura, M.I. Phillips, Losartan potassium, a nonpeptide
antagonist of angiotensin II, chronically administered p.o. does not
readily cross the blood brain barrier, Eur. J. Pharmacol. 219 (1992) [21]
147–151.
[2] E. Castre ́ n, J.M. Saavedra, Repeated stress increases the density of
angiotensin II binding sites in rat paraventricular nucleus and
subfornical organ, Endocrinology 122 (1988) 370–372. [22]
[3] J. Culman, C. von Heyer, B. Piepenburg, W. Rascher, T. Unger,
Effects of systemic treatment with irbesartan and losartan on central
responses to angiotensin II in conscious, normotensive rats, Eur. J. [23]
Pharmacol. 367 (1999) 255–265.
[4] F.M.J. Heemskerk, S. Zorad, A. Seltzer, J.M. Saavedra, Characteri- [24]
125
zation of brain angiotensin II AT receptor subtype using [ I]CGP
2

42112A, Neuroreport 4 (1993) 103–105. [25]
[5] F.M.J. Heemskerk, J.M. Saavedra, Quantitative autoradiography of
125
angiotensin II AT receptors with [ I]CGP 42112, Brain Res. 677
2

(1995) 29–38. [26]
[6] Y. Inada, T. Wada, M. Ojima, T. Sanada, Y. Shibouta, R. Kanagawa,
Y. Ishimura, Y. Fujisawa, K. Nishikawa, Protective effects of
candesartan cilexetil (TCV-116) against stroke, kidney dysfunction
and cardiac hypertrophy in stroke-prone spontaneously hypertensive [27]
rats, Clin. Exp. Hypertens. 19 (1997) 1079–1099.
[7] T. Inagami, D.-F. Guo, Y. Kitami, Molecular biology of angiotensin
II receptors: an overview, J. Hypertens. 12 (1994) 583–594.
[8] O. Jo ̈hren, T. Inagami, J.M. Saavedra, AT , AT and AT [28]
1A 1B 2

angiotensin II receptor subtype gene expression in rat brain,
Neuroreport 6 (1995) 2549–2552.
